
Purdue Pharma and its subsidiaries develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers.
Purdue’s confirmed Plan of Reorganization (“Plan”) was vacated on appeal by the United States District Court for the Southern District of New York. Purdue is appealing the ruling while simultaneously continuing its efforts to forge yet further consensus around a Plan that will deliver billions of dollars to the American people for opioid abatement.
The District Court decision does not affect Purdue’s operational stability or its ability to produce its many medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers. The company continues serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives. Upon emergence from bankruptcy, substantially all of Purdue’s assets would be transferred to a new company with a public-minded mission.
This new company will be governed by new independent board members, and will operate in a responsible and sustainable manner taking into account long-term public health interests relating to the opioid crisis. The company will continue serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.
Purdue’s confirmed Plan of Reorganization (“Plan”) was vacated on appeal by the United States District Court for the Southern District of New York. Purdue is appealing the ruling while simultaneously continuing its efforts to forge yet further consensus around a Plan that will deliver billions of dollars to the American people for opioid abatement.
The District Court decision does not affect Purdue’s operational stability or its ability to produce its many medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers. The company continues serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives. Upon emergence from bankruptcy, substantially all of Purdue’s assets would be transferred to a new company with a public-minded mission.
This new company will be governed by new independent board members, and will operate in a responsible and sustainable manner taking into account long-term public health interests relating to the opioid crisis. The company will continue serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.
Location: United States, Connecticut, Stamford
Employees: 5001-10000
Founded date: 1991
Mentions in press and media 41
Date | Title | Description |
21.06.2025 | Purdue Pharma's Opioid Settlement: A Turning Point in the Battle Against Addiction | The opioid crisis has been a relentless storm, wreaking havoc across America. Purdue Pharma, the maker of OxyContin, stands at the eye of this storm. A proposed $7 billion settlement could be a beacon of hope. If approved, it would mark one... |
20.06.2025 | Purdue Pharma’s $7B opioid settlement plan could get votes from victims and cities | If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers and pharmacies accountable for the opioid epidemic that started rising in the... |
18.06.2025 | Purdue Pharma’s $7B opioid settlement could advance after states back it | If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers and pharmacies accountable for the opioid epidemic that started rising in the... |
18.06.2025 | Attorney General Bird Announces $37.8 Million Opioid Settlement from Purdue Pharma | DES MOINES -- Attorney General Brenna Bird today announced that Iowa has agreed to sign on to a $7.4 billion settlement with Purdue Pharma and its owners, the Sackler family. The settlement would resolve litigation against Purdue and the Sa... |
30.05.2025 | The Rise of Shadow AI: A New Era in Consulting | The consulting industry is undergoing a seismic shift. The rise of shadow AI is transforming how firms operate, threatening traditional roles and redefining productivity. As consulting giants like McKinsey and PwC announce significant layof... |
28.05.2025 | McKinsey slashes 10 per cent of jobs in major overhaul | Consulting giant McKinsey has unleashed one of the largest job culls in the company’s history after ten per cent of staff faced the chop. The New York-headquartered firm has reversed major expansion plans, which peaked during the pandemic, ... |
21.03.2025 | The Biotech Boom and the Opioid Reckoning: A Tale of Two Industries | In the heart of Europe, a new wave of biotech innovation is rising. Sofinnova Partners has closed a €165 million fund, the Sofinnova Biovelocita II. This fund is a beacon for startups, illuminating the path for groundbreaking therapies. It’... |
19.03.2025 | Purdue Pharma files new bankruptcy plan for $7.4 billion opioid settlement | Purdue Pharma files new bankruptcy plan for $7.4 billion opioid settlement By Dietrich KnauthMarch 19, 20259:00 AM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link Bottles of prescription painkiller... |
25.01.2025 | Bankrupt Purdue buys time to advance $7.4 billion opioid deal | Bankrupt Purdue buys time to advance $7.4 billion opioid deal By Dietrich KnauthJanuary 24, 202510:35 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link A pharmacist holds prescription painkiller O... |
23.01.2025 | Purdue Pharma and owners to pay $7.4B in settlement over OxyContin’s toll | - |
Show more